Pneumococcal Vaccine Candidate MVX01

Streptococcus pneumoniae is the leading bacterial cause of community acquired pneumonia (CAP) and meningitis, and a significant cause of otitis media, sinusitis, and bacteremia. Pneumococcal disease results in >1 million deaths worldwide each year. 


S. pneumoniae is surrounded by a polysaccharide capsule that protects the bacterium from destruction by host immune cells. Antibodies to the capsule are protective and the current commercial vaccines against S. pneumoniae contain the polysaccharide serotypes most commonly observed in invasive pneumococcal disease (IPD).  However, the emergence of serotypes in IPD that are not covered by the existing vaccines is a growing concern and has renewed interest in the development of serotype-independent ‘universal’ vaccines against S. pneumoniae.

Matrivax is developing MVX01 - a new pneumolysin-fusion protein

that provides ‘serotype-independent’, global protection against invasive pneumococcal disease. MVX01 is undergoing IND-enabling studies, with an IND planned in the coming months.

© 2020 Matrivax Research and Development Corporation

650 Albany Street, Suite 117, Boston, MA 02118

LI-In-Bug.png